Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, Piper Sandler Analyst Says

Key Points

• Piper Sandler raised its price target on Neurocrine to $207 and kept an overweight rating, implying roughly a 43.5% upside from the current stock price.
• Analysts' consensus is a Moderate Buy with an average target of $182.35, while recent results show revenue of about $805–$811M (up ~28% YoY) driven by INGREZZA even as EPS and estimates have shown variability.
• Institutional investors own about 92.6% of the company, with large stake increases from AQR, UBS, Norges Bank and JPMorgan, indicating strong institutional interest.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) had its price target hoisted by Piper Sandler from $190.00 to $207.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has an "overweight" rating on the stock. Piper Sandler's target price suggests a potential upside of 43.51% from the stock's current price.

A number of other brokerages also recently weighed in on NBIX. UBS Group dropped their target price on Neurocrine Biosciences from $188.00 to $178.00 and set a "buy" rating on the stock in a report on Friday, January 23rd. Truist Financial dropped their target price on Neurocrine Biosciences from $169.00 to $140.00 and set a "buy" rating on the stock in a report on Tuesday, February 17th. Royal Bank Of Canada dropped their price objective on Neurocrine Biosciences from $180.00 to $177.00 and set an "outperform" rating on the stock in a report on Thursday, February 12th. Wedbush increased their price objective on Neurocrine Biosciences from $166.00 to $176.00 and gave the stock an "outperform" rating in a report on Wednesday. Finally, JPMorgan Chase & Co. increased their price objective on Neurocrine Biosciences from $176.00 to $177.00 and gave the stock an "overweight" rating in a report on Thursday, March 12th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $182.35.

Neurocrine Biosciences Price Performance

Shares of NASDAQ NBIX traded up $9.18 during trading on Wednesday, hitting $144.24. 848,705 shares of the company were exchanged, compared to its average volume of 1,145,246. The company has a market cap of $14.51 billion, a price-to-earnings ratio of 31.02, a PEG ratio of 0.67 and a beta of 0.34. Neurocrine Biosciences has a 1 year low of $115.66 and a 1 year high of $160.18. The firm's fifty day moving average price is $130.37 and its 200 day moving average price is $137.72.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.36 by ($0.48). Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The firm had revenue of $805.50 million for the quarter, compared to analyst estimates of $804.21 million. During the same period last year, the firm earned $1.69 EPS. The company's quarterly revenue was up 28.3% compared to the same quarter last year. On average, research analysts forecast that Neurocrine Biosciences will post 6.57 earnings per share for the current year.

Institutional Trading of Neurocrine Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC lifted its position in Neurocrine Biosciences by 83.7% in the 3rd quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company's stock valued at $388,435,000 after acquiring an additional 1,263,633 shares in the last quarter. Norges Bank acquired a new position in shares of Neurocrine Biosciences during the 4th quarter worth about $162,664,000. UBS Group AG grew its stake in Neurocrine Biosciences by 169.8% in the 4th quarter. UBS Group AG now owns 983,528 shares of the company's stock valued at $139,494,000 after buying an additional 618,956 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Neurocrine Biosciences by 11.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,730,152 shares of the company's stock valued at $664,019,000 after buying an additional 468,405 shares during the last quarter. Finally, Zurich Insurance Group Ltd FI acquired a new position in Neurocrine Biosciences in the 4th quarter valued at about $65,162,000. Institutional investors own 92.59% of the company's stock.

Key Headlines Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Wedbush raised its price target on NBIX to $176 and kept an "outperform" rating, implying meaningful upside and likely supporting buy-side interest. Benzinga
• Positive Sentiment: Q1 results beat expectations: EPS and revenue topped consensus, net product sales rose ~44% YoY to roughly $811M, and management reaffirmed full-year INGREZZA sales guidance of $2.7–$2.8B — data that directly support valuation and near-term cash flow visibility. Q1 Press Release
• Positive Sentiment: INGREZZA sales were a key driver of the better-than-expected quarter, cited by multiple outlets — supporting the commercial growth story and analyst upgrades. Investing.com
• Positive Sentiment: Publication of expert recommendations for glucocorticoid dose reduction after initiating CRENESSITY (crinecerfont) — published in a peer-reviewed journal — should help clinicians reduce steroid burden in CAH patients and may accelerate real-world adoption. PR Newswire - CRENESSITY publication
• Positive Sentiment: Neurocrine announced a definitive agreement to acquire Soleno Therapeutics (including VYKAT XR for hyperphagia in Prader‑Willi), expanding the company's pipeline and near-term commercial opportunities; expected close in Q2 2026. Acquisition announcement
• Neutral Sentiment: Pipeline progress: initiation of a Phase 2 study of NBI-1117570 (M1/M4 agonist) in schizophrenia — a positive clinical update but earlier-stage and longer horizon for value realization. Seeking Alpha - presentation
• Neutral Sentiment: Analyst/market coverage and events: company to present at the Bank of America Health Care Conference (May 12) and several earnings call transcripts/analyst notes are circulating — useful for deeper due diligence but not immediate catalysts. Conference notice

Neurocrine Biosciences Company Profile

Neurocrine Biosciences NASDAQ: NBIX is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine's operations encompass drug discovery, clinical development and commercialization activities.

The company's lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.